Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How does residual DCIS after neoadjuvant chemotherapy impact prognosis if there is a CR of the invasive disease?
Answer from: Radiation Oncologist at Community Practice
The majority of studies suggest residual DCIS has the same outcome as pCR with no invasive disease and thus is still treated as pCR in practice.
Sign in or Register to read more
17488
Related Questions
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
Does a post-surgical hematoma in the breast affect your recommendations for partial breast RT?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
When should the dissected axilla (levels I-II) be included when delivering RNI?
Is DCISionRT appropriate for multifocal DCIS?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
How do you choose between ALND and RNI in the setting of LYMPHA or S-Lympha surgery?
Would you feel comfortable doing high tangents with ultra-hypofractionation?
In a patient with T2N0 breast cancer with skin involvement s/p lumpectomy and negative margins, if you are offering whole breast radiation, would you bolus your tangent fields?